Medical Technology: Monthly Injection for Ozempic and Wegovy (Semaglutide)
Monday, 9 September 2024, 03:00
Advancements in Semaglutide Administration
A recent discovery in medical technology reveals that a slow-release form of semaglutide could permit individuals to receive weight-loss injections of Wegovy or Ozempic on a monthly basis, enhancing the convenience for patients. The formulation involves a hydrating gel that steadily releases the medication, addressing the burden of weekly dosing.
Technical Insights
- Lead researcher Dr. Claire Megret highlights the development of a small gel depot encasing semaglutide.
- This hydrogel functioned effectively in laboratory trials involving animals.
- Future studies on pigs are planned, paving the way for eventual human clinical trials.
Such innovations could significantly improve adherence to diabetes and weight-loss treatments, facilitating better health outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.